首都医科大学学报 ›› 2011, Vol. 32 ›› Issue (6): 754-758.doi: 10.3969/j.issn.1006-7795.2011.06.009

• 耳鼻咽喉头颈外科进展 • 上一篇    下一篇

PCNA、neuregulin-1、erbB-2在听神经瘤中的表达 与肿瘤生物学行为相关性分析

冯娟娟1, 夏寅2   

  1. 1. 江苏省扬州市第一人民医院耳鼻咽喉科,扬州 225000;2. 首都医科大学附属北京同仁医院耳鼻咽喉头颈外科, 北京 100730
  • 收稿日期:2011-09-16 修回日期:1900-01-01 出版日期:2011-12-21 发布日期:2011-12-21
  • 通讯作者: 夏寅

Relevance between the expression of PCNA, neuregulin-1 and erbB-2 and biological behavior of acoustic neuroma

FENG Juan-juan1, XIA Yin2   

  1. 1. Department of Otorhinolaryngology, The First People's Hospital of Yangzhou, Yangzhou 225000, China;2. Department of Otorhinolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China
  • Received:2011-09-16 Revised:1900-01-01 Online:2011-12-21 Published:2011-12-21

摘要: 目的 探讨肿瘤增生细胞核抗原(proliferating cell nuclear antigen,PCNA)、神经调节因子-1(neuregulin-1)及其受体erbB-2在听神经瘤组织标本中表达的意义及其与肿瘤生长特性的相关性。方法 回顾性分析27例接受听神经瘤手术患者的临床资料,27例蜡封标本经病理证实均为听神经瘤,利用免疫组织化学方法对其病理标本石蜡切片进行PCNA、neuregulin-1、erbB-2染色。结果 在27例听神经瘤标本中,PCNA阳性率为92.6%(25/27);neuregulin-1阳性率为81.4%(22/27),erbB-2在全部听神经瘤病理标本中均无表达。PCNA阳性表达与性别、年龄、肿瘤侧别和大小均无相关性;PCNA增生指数与病程(F=5.011,P=0.015)及肿瘤临床生长速率有关(t=-3.360,P=0.003)。Neuregulin-1阳性表达强度与患者性别、年龄、肿瘤侧别和大小均无相关性,neuregulin-1表达强度在患者病程<1年组比>1年组明显增高,在肿瘤临床年生长速率<10 mm组低于肿瘤临床年生长速率≥10 mm组,但差异无统计学意义。Neuregulin-1阳性表达强度与PCNA增生指数呈正相关(r=0.425,P=0.027)。结论 PCNA与肿瘤生长和细胞增生有关,神经调节因子neuregulin-1参与了听神经瘤生长的生物学行为,作为neuregulin-1功能性受体的erbB-2在听神经瘤中的表达及其所起的作用有待进一步大标本量研究论证。听神经瘤的临床行为与肿瘤增生有关,目前临床上提供的肿瘤部分临床特征可在一定程度上反映听神经瘤的增生趋势。

关键词: 听神经瘤, 增生细胞核抗原, 神经调节因子-1, erbB-2

Abstract: Objective To examin the relationship between the expression of proliferating cell nuclear antigen(PCNA), neuregulin-1 and its receptor erbB-2 in acoustic neuroma and the growth characteristics of the tumor. Methods The clinical information of 27 patients with acoustic neuroma were reviewed retrospectively. Paraffin embedded acoustic neuroma samples confirmed by pathology from the 27 patients were included in the study. The expression of PCNA, neuregulin-1 and erbB-2 in acoustic neuroma was determined by immunohistochemistry. Results In all the 27 cases, the positive rate of PCNA was 92.7%(25/27) and the positive rate of neuregulin-1 was 81.4%(22/27). ErbB-2 expressed in none of the cases. There was no significant relationship between the expression of PCNA with gender, age, the side and size of the tumors, but there was significant difference between the expression of PCNA with the course(F=5.011, P=0.015) and clinical growth rate(t=-3.360, P=0.003) of the disease. There was no significant relationship between the expression of neuregulin-1 with gender, age, the side, size and course of the tumors. Although the expression of neuregulin-1 in the tumors of course less than 1 year was higher than that of the course more than 1 year, but the difference was not statistically significant. The expression of neuregulin-1 in the tumors of clinical growth rate less than 10 mm/year was lower than that in the tumors with the clinical growth rate more than 10 mm/year, the difference was not statistically significant. The expression of neuregulin-1 and PCNA had positive correlation(r=0.425, P=0.027). Conclusion PCNA is related with the growth of acoustic neuroma, and reflects proliferation activities of tumor cells in acoustic neuroma. Neuregulin-1 might participate in the biological behavior of acoustic neuroma. As the functional receptor of neuregulin-1, the expression of erbB-2 and its role in acoustic neuroma need further study in more cases. The clinical behavior of acoustic neuroma relates to tumor growth. Some characteristics of acoustic neuroma can reflect the trend of tumor

Key words: neuromas acoustic, proliferating cell nuclear antigen(PCNA), neuregulin-1, erbB-2

中图分类号: